Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology, Inc. (KURA): Hedge Funds Can’t Make Up Their Minds
07:21pm, Tuesday, 10'th Dec 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
05:00pm, Sunday, 08'th Dec 2019
– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR).
Kura Oncology to Participate in Piper Jaffray Healthcare Conference
12:30pm, Tuesday, 26'th Nov 2019
SAN DIEGO, Nov. 26, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.
Kura Oncology Requires Plenty of Patience by Investors
10:51am, Monday, 25'th Nov 2019
During the Lightning Round segment of Mad Money Friday night one caller inquired about Kura Oncology : "This has personalized cancer treatments and I like it for speculation," said Jim Cramer. In th
Edited Transcript of KURA earnings conference call or presentation 5-Nov-19 9:30pm GMT
09:29pm, Friday, 15'th Nov 2019
Q3 2019 Kura Oncology Inc Earnings Call
Kura Oncology to Present at Stifel Healthcare Conference
12:30pm, Tuesday, 12'th Nov 2019
SAN DIEGO, Nov. 12, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.
Hedge Funds Have Never Been This Bullish On Kura Oncology, Inc. (KURA)
07:26pm, Saturday, 09'th Nov 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and thes
Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
02:06pm, Wednesday, 06'th Nov 2019
SAN DIEGO, Nov. 06, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
09:05pm, Tuesday, 05'th Nov 2019
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of.
